XML 55 R39.htm IDEA: XBRL DOCUMENT v3.22.4
SEGMENT INFORMATION (Tables)
3 Months Ended
Jan. 31, 2023
Segment Reporting [Abstract]  
Segment Profitability and Segment Assets
The profitability of each of the segments is measured after excluding items such as transformational initiatives, acquisition and integration costs, amortization of intangible assets related to business combinations, interest income, interest expense and other items as noted in the reconciliations below:
Three Months Ended
 January 31,
 20232022
 (in millions)
Net Revenue:
Life Sciences and Applied Markets$1,033 $976 
Diagnostics and Genomics342 339 
Agilent CrossLab381 359 
Total net revenue$1,756 $1,674 
Segment Income From Operations:
Life Sciences and Applied Markets$314 $282 
Diagnostics and Genomics59 68 
Agilent CrossLab103 91 
Total segment income from operations$476 $441 
The following table reflects segment assets under our management reporting system. Segment assets include allocations of corporate assets, goodwill, net other intangibles and other assets. Unallocated assets primarily consist of cash, cash equivalents, short-term and long-term investments, deferred tax assets, right-of-use assets and other assets.  
 January 31,
2023
October 31,
2022
(in millions)
Segment Assets:  
Life Sciences and Applied Markets$4,004 $3,955 
Diagnostics and Genomics3,520 3,489 
Agilent CrossLab962 869 
Total segment assets$8,486 $8,313 
Reconciliation of segment results to total enterprise results
The following table reconciles segment income from operations to Agilent’s total enterprise income before taxes: 
Three Months Ended
 January 31,
 20232022
 (in millions)
Total segment income from operations$476 $441 
Transformational initiatives(7)(4)
Amortization of intangible assets related to business combinations(36)(51)
Acquisition and integration costs(2)(7)
Change in fair value of contingent consideration(1)(3)
Other(4)— 
Interest income
Interest expense(25)(21)
Other income (expense), net (1)
— (37)
Income before taxes, as reported$410 $319 

(1) For the three months ended January 31, 2023 and 2022, other income (expense), net includes net (gains) losses on the fair value of equity securities.